Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Stopped PI decided to withdraw the study after it opened for enrollment but before any patients were enrolled

Conditions

• Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
• Primary Myelofibrosis

Interventions

• BIOLOGICAL: Durvalumab
• OTHER: Laboratory Biomarker Analysis

Sponsor

Northwestern University

Collaborators

• [object Object]
• [object Object]
• [object Object]